Supreme Court rebuffs another J&J appeal, leaving $140M failure-to-warn judgment intact

Tracy Staton Johnson & Johnson is zero for two at the U.S. Supreme Court this month. Last week, the court refused to weigh its final appeal against a $ 124 million penalty ...

Big question for Pfizer: Will Enbrel’s EU biosim bring on the pain?

Carly Helfand Amgen and Pfizer's Enbrel officially has a biosimilar rival in Europe. And if the rollout goes anything like the recent EU launch of Remicade copy Remsima, the blockbuster ...

Samsung and Biogen win first EU approval for an Enbrel copycat

Damian Garde A joint venture between Biogen and South Korean giant Samsung won Europe's first approval for a lower-cost version of Amgen and Pfizer's blockbuster Enbrel, planning ...

Oncobiologics looks to a $115M IPO to back its biosimilars business

John Carroll Oncobiologics CEO Pankaj Mohan is turning to a turbulent public market to provide the next big injection of cash that will be needed to keep his knockoffs of Humira and ...

It’s Merck vs. Merck as name confusion, complicated by social media, leads to legal showdown

Eric Palmer Merck has won a legal battle over Merck, which in return says it will file a lawsuit against Merck. It sounds confusing, but confusion is the essence of the legal battle ...

Botched drug trial leaves one patient ‘brain-dead,’ 5 hospitalized

Damian Garde A botched Phase I trial has left 6 patients in serious condition with one effectively "brain-dead," according to the French government, which has opened an investigation. FierceBiotech ...

Cardiorentis bags $60M as PhIII nears end; J&J backs HIV player; Novartis nears Horsham sale

Nick Paul Taylor Our top stories in this week's EuroBiotech Report involve the transfer of more than $ 100 million (€92 million) from the wallets of investors to the bank ...

BioLineRx joins immuno-oncology scrum through Keytruda combo deal

Nick Paul Taylor BioLineRx has become the latest company to stake its claim for a spot on the burgeoning roster of immuno-oncology combinations. The small biotech is aiming to muscle ...

Biotech has a problem with women? Or is it the other way around?

John Carroll FierceBiotech News

Fresh investment in Novimmune brings fundraising haul up to $245M

Nick Paul Taylor Novimmune has tapped existing investors for CHF 30 million ($ 30 million) to support the advance of its pipeline, particularly a therapy for a rare immune system disorder ...

Biden maps out a ‘moonshot’ approach to cancer with plans to ‘break down silos’ in R&D

Damian Garde Vice President Joe Biden fleshed out his plans to take the lead on a global effort to bolster cancer research, hoping to unite industry and academia to push new therapies ...

Celgene ends horse race for Hugin’s successor, tapping Mark Alles as new CEO

Tracy Staton Celgene's Mark Alles will join biopharma's slate of new CEOs in March as part of a management reshuffling at the $ 9 billion-plus biotech. Current chief Bob ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS